Assessing Zanubrutinib, Obinutuzumab, Venetoclax for Previously Untreated CLL
December 17th 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.
Practice Pearl 1: Role of PARP Inhibitors in Ovarian Cancer
December 17th 2021Sarah Hayward, PharmD, BCOP; Jennifer MacDonald, PharmD, BCOP; and Bradley J. Monk, MD, FACS, FACOG, discuss the relevance of PARP inhibition in the treatment of ovarian cancer and comment on the use of biomarker testing for treatment initiation.
Individuals With Chronic Lymphocytic Leukemia Benefit More From iFCR Therapy Than Older Individuals
December 13th 2021Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.
Ongoing Clinical Trials Look to Assess Optimization or Combination Treatments of Asciminib in CML
December 13th 2021Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.
How Recent Asciminib Trial Data May Impact Treatment Strategies, Approaches for CML
December 13th 2021Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how the ASCEMBL study data may impact treatment strategies and approaches for patients with chronic myeloid leukemia.